← CRISPR Therapeutics AG (CRSP) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
CRISPR Therapeutics AG (CRSP)
Biological Products, (No Diagnostic Substances) · market cap $5.5B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
4
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
CRISPR Therapeutics AG (CRSP) is a Swiss-American gene editing biotech with two Phase 2 clinical assets — CTX131 in clear cell renal cell carcinoma and CTX112 in B-cell lymphoma — and no recent approved-product revenue of scale. The company carries a market cap of ~$5.1B but reported only $4M in 2025 revenue against a $582M net loss, and its disclosed cash position of $60.5M implies a runway of roughly 1.7 months, flagging an acute near-term financing imperative.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
- 2027-06-06 (est.)Phase 3 · CTX001imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CTX131 | Phase 2 | Clear Cell Renal Cell Carcinoma |
| CTX112 | Phase 2 | B-cell Lymphoma |
| CTX340 | Phase 2 | Hypertension |
| CTX001 | Phase 3 | Beta-Thalassemia |
Price & technical context
3-month
-7.7%
6-month
+13.6%
12-month
-14.5%
52-wk range
$44.34–$76.78
vs 50-day MA
+2.3%
vs 200-day MA
+4.0%
Realized vol
59.5%
Max drawdown
-43.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CRSP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.